Helping an Emerging Biotech Navigate Complex Clinical Development
Preparing for a first-in-human clinical trial presents significant challenges, particularly for emerging biotech companies with limited clinical experience, constrained patient populations, and the need to satisfy regulatory expectations.
Phastar partnered with a biotechnology company developing an early-phase oncology program to design a robust dose-finding study that would maximize learning while maintaining scientific and regulatory confidence.
The Challenge
The client required a study design that could:
- Make efficient use of a limited patient population
- Support both dose escalation and early efficacy evaluation
- Meet FDA and EMA expectations
- Provide a clear and defensible path to trial initiation
Download the Full Case Study
Discover how Phastar combined innovative Bayesian methodology, regulatory expertise, and end-to-end statistical leadership to help an emerging biotech successfully launch its first-in-human oncology program.
